The GR has been shown to be increasingly present in androgen-deprived prostate cancer patients (78% vs. 38% of untreated patients)62, and expression of GR is increased in xenografts that are resistant to ARN-509 (apalutamide)63. Here, NR3C1 is linked to prostate carcinoma.